All Articles

Struggling biotech Tempest Therapeutics adds finance and medical heavyweights to its board. Is this a strategic reset or a last-ditch effort to survive?

Kevin Knight, the architect of the Knight-Swift merger, retires, ending a founder's era. We analyze the strategic shift and the road ahead for the titan.

A $1.1 billion fraud reckoning hits Ohio as the SBA intensifies its crackdown, raising questions about due process and the true cost of pandemic relief.

Trinity Industries heads to a key conference with a story of leasing strength and manufacturing headwinds. Here's the story behind the numbers for investors.

As TopBuild shareholders face a critical merger deadline, QXO is assembling an industry titan. This move isn't just about size; it's a bid to reshape the future.

As Royalty Pharma prepares for a key investor conference, we explore the powerful, low-profile business model that funds blockbuster drugs and shapes innovation.

Chinese vaccine maker Zhengye Biotechnology has 180 days to save its Nasdaq listing. But the sub-$1 stock price is just a symptom of deeper financial decay.

Rubrik reports a stellar Q1 with 32% ARR growth, turning a profit. Its strategic shift to secure agentic AI is redefining data protection and winning large enterprises.

Lululemon's latest earnings reveal a stark divide. Surging international growth is being undermined by a worrying slowdown in its most important market.

SpaceX's record-shattering $75 billion IPO promises unprecedented access for retail investors, but a sky-high valuation and governance red flags loom large.

Visure Solutions unveils Engineering Intelligence, a framework aiming to solve AI's context problem in regulated industries like aerospace and automotive.

As HON opens its Chicago flagship, it’s not just showcasing furniture. It’s building a physical blueprint for the hybrid, sustainable networks that define modern work and education.

HELP USA's recent gala honored leaders in housing, but the real story is the innovative fusion of finance, policy, and healthcare creating scalable solutions.

With a fresh $287.5M, Keystone Acquisition Corp. is targeting US industrial innovation. But can it find a winner in 2026's competitive SPAC market?

A new breed of fund offers Main Street a taste of Silicon Valley's private unicorns. But as Powerlaw Corp. opens the door, are investors ready for the risks?

Interim Phase 3 data shows Otsuka's VOYXACT not only meets surrogate endpoints but preserves kidney function, a strategic masterstroke in the competitive nephrology market.

A $90M investment in a homeless shelter is more than charity; it's a blueprint. Sun Life's model signals a shift from philanthropy to strategic impact investing.

Washington recycled over 1M gallons of paint in 2025, but the real story is the business model behind it—a blueprint for corporate responsibility.

The 2026 World Cup isn't just a test for athletes. It's a massive stress test for global payment systems and a prime target for sophisticated fraud.

A new class of doctor is bridging the gap between lab and patient. Meet the physician-scientists tackling deadly diseases with revolutionary new approaches.